Qiang Zhao

Director/Board Member at Shanghai Haihe Biopharma Co., Ltd.

61 year

Utilities

Commercial Services

Producer Manufacturing

Profile

Qiang Zhao is an Independent Director at Shanghai Haihe Biopharma Co., Ltd.
since 2020.
Prior to this, he held the position of Independent Director at Jionto Energy Investment Co., Ltd.
Hebei.
He also served as an Independent Director at Beijing Chieftain Control Engineering Technology Co., Ltd.
from 2017 to 2023.

Qiang Zhao active positions

Companies	Position	Start
Shanghai Haihe Biopharma Co., Ltd. Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.	Director/Board Member	2020-09-07

All active positions of Qiang Zhao

Former positions of Qiang Zhao

Companies	Position	End
BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD.	Director/Board Member	2023-06-09
JOINTO ENERGY INVESTMENT CO., LTD. HEBEI	Director/Board Member	-

See the detail of Qiang Zhao's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Qiang Zhao's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
JOINTO ENERGY INVESTMENT CO., LTD. HEBEI	Utilities
BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD.	Producer Manufacturing

Private companies	1
Shanghai Haihe Biopharma Co., Ltd. Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.	Commercial Services